Share on StockTwits

Shares of Humana (NYSE:HUM) have earned a consensus recommendation of “Hold” from the twenty-six brokerages that are currently covering the company, StockRatingsNetwork reports. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $125.80.

HUM has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Humana in a research note on Thursday, June 19th. They now have a $131.00 price target on the stock. Separately, analysts at Stifel Nicolaus upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. They now have a $155.00 price target on the stock. Finally, analysts at Stifel upgraded shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, June 6th. They now have a $155.00 price target on the stock.

Humana (NYSE:HUM) traded up 0.32% on Tuesday, hitting $127.73. 148,346 shares of the company’s stock traded hands. Humana has a 52-week low of $82.14 and a 52-week high of $127.67. The stock’s 50-day moving average is $122. and its 200-day moving average is $109.5. The company has a market cap of $19.771 billion and a P/E ratio of 17.90.

Humana (NYSE:HUM) last released its earnings data on Wednesday, May 7th. The company reported $2.35 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.94 by $0.41. During the same quarter last year, the company posted $2.69 earnings per share. Analysts expect that Humana will post $7.81 EPS for the current fiscal year.

Humana Inc (NYSE:HUM) is a health care company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.